Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics, Inc.

Ondas Holdings Inc., through its subsidiaries, provides private wireless, drone, and automated data solutions. The company operates in two segments, Ondas Networks and American Robotics. The company designs, develops, manufactures, sells, and supports FullMAX, a software defined radio (SDR) platform for wide-area broadband networks. Its FullMAX SDR platform enables secure and reliable industrial-grade connectivity for truly mission-critical applications. The company also offers Scout Drone, an AI-powered drone with imaging payloads; the ScoutBase, a ruggedized base station for housing, charging, data processing, and cloud transfer; and ScoutView, an American robotics analytics and user interface software package. It serves users in rail, energy, mining, agriculture, and critical infrastructure markets in the United States and internationally. The company is headquartered in Waltham, Massachusetts.

Ondas Holdings Inc.

RXO provides truckload freight transportation brokerage in the United States. The company, through a proprietary digital freight marketplace, offers access to truckload capacity and complementary brokered services of managed transportation, last mile, and freight forwarding. The company is based in Charlotte, North Carolina.

RXO, Inc.

As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Atlantic International Corp.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.

Acushnet Holdings Corp. designs, develops, manufactures, and distributes golf products in the United States, Europe, the Middle East, Africa, Japan, Korea, and internationally. The company operates through four segments: Titleist Golf Balls, Titleist Golf Clubs, Titleist Golf Gear, and FootJoy Golf Wear. It offers golf balls under the Titleist brand; golf clubs, such as drivers, fairways, hybrids, and irons under the Titleist brand name; wedges under the Vokey Design brand; and putters under the Scotty Cameron brand. The company also provides golf bags, headwear, golf gloves, travel products, head covers, and other golf accessories, as well as offers customization and personalization of products in Titleist golf gear. In addition, it offers golf shoes, gloves, golf outerwear, and men's and women's golf apparels under the FootJoy brand; and ski, golf, and lifestyle apparels under the KJUS brand name. It sells its products through on-course golf shops and golf specialty retailers, as well as through representatives, other retailers, and online. The company was formerly known as Alexandria Holdings Corp. and changed its name to Acushnet Holdings Corp. in March 2016. Acushnet Holdings Corp. was founded in 1910 and is headquartered in Fairhaven, Massachusetts.

Acushnet Holdings Corp.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. Its flagship property is the Lost Creek project comprising a total of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 48,000 acres located in the Great Divide Basin, Wyoming. The company was incorporated in 2004 and is headquartered in Littleton, Colorado.

Ur-Energy Inc.

Red Cat Holdings, Inc., through its subsidiaries, provides various products, services, and solutions to the drone industry. It offers commercial and government unmanned aerial vehicle technology for reconnaissance, public safety, and inspection applications. The company also provides First Person View (FPV) video goggles; and software and hardware solutions that enable drones to complete inspection services in locations where global positioning systems are not available. In addition, it is involved in the sales of FPV drones and equipment primarily to the consumer marketplace. Red Cat Holdings, Inc.is based in San Juan, Puerto Rico.

Red Cat Holdings, Inc.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Vox Royalty Corp. operates as a mining royalty and streaming company. The company holds a portfolio of 56 royalties and streaming assets, as well as 1 royalty option. It operates in Australia, Canada, Peru, Brazil, South Africa, Mexico, the United States, Madagascar, the Cayman Islands, and Nigeria. The company was founded in 2014 and is based in Toronto, Canada.

Vox Royalty Corp.

P10, Inc., together with its subsidiaries, operates as a multi-asset class private market solutions provider in the alternative asset management industry in the United States. The company offers private equity, venture capital, private credit, impact investing, and private credit services, as well as primary fund of funds, secondary investment, and direct and co-investments services. It also provides tax credit transaction and consulting services. The company was founded in 1992 and is headquartered in Dallas, Texas.

P10, Inc.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for utility, commercial and industrial, and renewable energy markets in the United States. It offers stationary battery storage solutions. The company's flagship product is the Eos Znyth DC battery system designed to meet the requirements of the grid-scale energy storage market. Eos Energy Enterprises, Inc. was founded in 2008 and is headquartered in Edison, New Jersey.

Eos Energy Enterprises, Inc.

i-80 Gold Corp., a mining company, engages in the exploration, development, and production of gold and silver mineral deposits in the United States. It holds a 100% interest in the Lone Tree property covering an area of approximately 12,000 acres located in Battle Mountain-Eureka, Northern Nevada; Ruby Hill property located in Battle Mountain Trend, Northern Nevada; McCoy-Cove project covering 31,000 acres located in Battle Mountain Trend, Nevada; and Buffalo Mountain property located in Battle Mountain Trend, Northern Nevada as well as controls Granite Creek Project located in Getchell Trend, Northern Nevada. The company was incorporated in 2020 and is headquartered in Reno, Nevada.

i-80 Gold Corp.

Carnival Corporation & plc operates as a leisure travel company. Its ships visit approximately 700 ports under the Carnival Cruise Line, Princess Cruises, Holland America Line, P&O Cruises (Australia), Seabourn, Costa Cruises, AIDA Cruises, P&O Cruises (UK), and Cunard brand names. The company also provides port destinations and other services, as well as owns and owns and operates hotels, lodges, glass-domed railcars, and motor coaches. It sells its cruises primarily through travel agents, tour operators, vacation planners, and websites. The company operates in the United States, Canada, Continental Europe, the United Kingdom, Australia, New Zealand, Asia, and internationally. It operates 87 ships with 223,000 lower berths. Carnival Corporation & plc was founded in 1972 and is headquartered in Miami, Florida.

Carnival Corporation & plc

Norwegian Cruise Line Holdings Ltd., together with its subsidiaries, operates as a cruise company in North America, Europe, the Asia-Pacific, and internationally. The company operates the Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands. It offers itineraries ranging from three days to a 180-days calling on various locations, including destinations in Scandinavia, Russia, the Mediterranean, the Greek Isles, Alaska, Canada and New England, Hawaii, Asia, Tahiti and the South Pacific, Australia and New Zealand, Africa, India, South America, the Panama Canal, and the Caribbean. As of December 31, 2021, the company had 28 ships with approximately 59,150 berths. It distributes its products through retail/travel advisor and onboard cruise sales channels, as well as meetings, incentives, and charters. Norwegian Cruise Line Holdings Ltd. was founded in 1966 and is based in Miami, Florida.

Norwegian Cruise Line Holdings Ltd.

Discover the most dynamic companies of the U.S. market, driving exceptional revenue growth across industries. This curated list highlights market leaders and emerging innovators achieving rapid expansion through cutting-edge technology, strategic execution, and customer-driven innovation.

From disruptive startups to established corporations, these high-growth organizations are redefining their sectors and capturing investor attention with their sustained financial momentum and scalable business models.

#	Company	Industry	Price	Vs 52W High	Market Cap	Analyst Target	P/E	Dividend	DCF	Score	Value	Profit	Growth	Health
1	Crinetics Pharmaceuticals, Inc... CRNX NASDAQ US	Biotechnology	$37.81 0.11 (-3.09%)	-34.80% vs $57.99	$3.96 B	$83.50	-9.41	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
2	Beam Therapeutics Inc. BEAM NASDAQ US	Biotechnology	$24.58 0.35 (-3.33%)	-32.54% vs $36.44	$2.50 B	$45.95	-35.65	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
3	CorMedix Inc. CRMD NASDAQ US	Biotechnology	$7.13 0.04 (23.01%)	-59.12% vs $17.43	$563.23 M	$13.21	5.62	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
4	TG Therapeutics, Inc. TGTX NASDAQ US	Biotechnology	$33.67 -0.02 (2.49%)	-27.56% vs $46.48	$5.38 B	$39.00	9.53	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
5	Ondas Holdings Inc. ONDS NASDAQ US	Communication E…	$9.46 -0.07 (-1.51%)	-38.12% vs $15.28	$4.38 B	$17.13	-16.40	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
6	RXO, Inc. RXO NYSE US	Trucking	$15.42 0.10 (-4.53%)	-17.50% vs $18.69	$2.53 B	$16.37	-21.33	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
7	Atlantic International Corp. ATLN NASDAQ US	Medical - Diagn…	$2.99 -0.35 (NaN%)	-43.05% vs $5.25	$237.07 M	-	-1.65	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
8	BridgeBio Pharma, Inc. BBIO NASDAQ US	Biotechnology	$71.61 -0.68 (0.95%)	-15.70% vs $84.94	$13.88 B	$98.97	-20.69	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
9	Acushnet Holdings Corp. GOLF NYSE US	Leisure	$94.36 -0.55 (-1.45%)	-9.98% vs $104.81	$5.53 B	$97.42	25.34	$0.96	-	0 / 100	- / 100	- / 100	- / 100	- / 100
10	Geron Corporation GERN NASDAQ US	Biotechnology	$1.77 0.02 (-7.43%)	-11.94% vs $2.01	$1.13 B	$4.00	-10.27	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
11	Ur-Energy Inc. URG AMEX US	Uranium	$1.42 -0.09 (NaN%)	-39.79% vs $2.35	$562.22 M	$2.30	-7.02	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
12	Red Cat Holdings, Inc. RCAT NASDAQ US	Computer Hardwa…	$12.26 -0.80 (13.07%)	-34.72% vs $18.78	$1.21 B	$22.00	-13.14	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
13	Nanobiotix S.A. NBTX NASDAQ FR	Biotechnology	$29.90 -2.86 (-1.36%)	-28.63% vs $41.89	$1.45 B	$26.00	-38.59	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
14	Ascendis Pharma A/S ASND NASDAQ DK	Biotechnology	$220.21 -6.48 (2.25%)	-11.42% vs $248.60	$13.52 B	$286.31	-48.92	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
15	Vox Royalty Corp. VOXR NASDAQ CA	Other Precious …	$5.23 -0.02 (0.00%)	-20.64% vs $6.59	$289.78 M	-	44.62	$0.06	-	0 / 100	- / 100	- / 100	- / 100	- / 100
16	P10, Inc. PX NYSE US	Asset Managemen…	$7.33 0.30 (-11.08%)	-45.58% vs $13.47	$805.57 M	$25.00	59.10	$0.15	-	0 / 100	- / 100	- / 100	- / 100	- / 100
17	Eos Energy Enterprises, Inc. EOSE NASDAQ US	Electrical Equi…	$4.50 -0.34 (4.36%)	-77.37% vs $19.86	$1.17 B	$15.42	-3.08	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
18	i-80 Gold Corp. IAUX AMEX US	Gold	$1.65 0.01 (NaN%)	-26.34% vs $2.24	$1.39 B	-	-6.90	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
19	Carnival Corporation & plc CCL NYSE US	Leisure	$25.08 -0.89 (-0.54%)	-26.30% vs $34.03	$34.74 B	$34.77	14.05	$0.15	-	0 / 100	- / 100	- / 100	- / 100	- / 100
20	Norwegian Cruise Line Holdings... NCLH NYSE US	Travel Services	$18.55 -0.81 (0.46%)	-31.73% vs $27.18	$8.45 B	$25.96	24.01	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100

Fastest Growing Companies By Revenue